College of Biological Engineering, Zhejiang University of Technology, Hangzhou, 310032, China.
Department of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, 12180, USA.
Appl Microbiol Biotechnol. 2016 Sep;100(18):7877-85. doi: 10.1007/s00253-016-7511-y. Epub 2016 Apr 14.
Heparosan, the capsular polysaccharide of Escherichia coli K5 having a carbohydrate backbone similar to that of heparin, has become a potential precursor for bioengineering heparin. In the heparosan biosynthesis pathway, the gene waaR encoding α-1-, 2- glycosyltransferase catalyze s the third glucosyl residues linking to the oligosaccharide chain. In the present study, a waaR deletion mutant of E. coli K5 was constructed. The mutant showed improvement of capsule polysaccharide yield. It is interesting that the heparosan molecular weight of the mutant is reduced and may become more suitable as a precursor for the production of low molecular weight heparin derived from the wild-type K5 capsular polysaccharide.
肝素聚糖是大肠杆菌 K5 的荚膜多糖,其碳水化合物主链与肝素相似,已成为生物工程肝素的潜在前体。在肝素聚糖生物合成途径中,编码 α-1,2-糖苷转移酶的 waaR 基因催化第三个葡萄糖基残基与寡糖链连接。在本研究中,构建了大肠杆菌 K5 的 waaR 缺失突变体。该突变体表现出荚膜多糖产量的提高。有趣的是,突变体的肝素聚糖分子量降低,可能更适合作为源自野生型 K5 荚膜多糖的低分子量肝素的前体。